BostonGene Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
300
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$120M
- Investors
-
3
BostonGene General Information
Description
Developer of a biomedical software designed for advanced patient analysis and personalized therapy. The company's software offers an artificial intelligence-powered molecular genetic and immune profiling platform to decode cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend effective treatments, enabling clinicians to get precise, clinically validated insights that drive precision medicine and advance oncology research.
Contact Information
Website
www.bostongene.comCorporate Office
- University Office Park III, 95 Sawyer Road
- Suite 500
- Waltham, MA 02453
- United States
Corporate Office
- University Office Park III, 95 Sawyer Road
- Suite 500
- Waltham, MA 02453
- United States
BostonGene Timeline
BostonGene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B2) | 05-Dec-2024 | $120M | Completed | Generating Revenue | ||
| 2. Later Stage VC (Series B) | 04-Mar-2022 | Completed | Generating Revenue | |||
| 1. Corporate | 24-Apr-2019 | $50M | $50M | Completed | Startup |
BostonGene Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | 50,000,000 | $0.000100 | $1 | $1 | 1x | $1 | 7.58% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
BostonGene Comparisons
Industry
Financing
Details
BostonGene Competitors (29)
One of BostonGene’s 29 competitors is Congenica, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Congenica | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Proscia | Venture Capital-Backed | Philadelphia, PA | ||||
| PierianDx | Private Equity-Backed | Creve Coeur, MO | ||||
| GenoSpace | Corporate Backed or Acquired | Boston, MA | ||||
| Arterys | Formerly VC-backed | San Francisco, CA |
BostonGene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BostonGene Patents
BostonGene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250166178-A1 | Techniques for tertiary lymphoid structure (tls) detection | Pending | 20-Nov-2023 | ||
| US-20250029677-A1 | Techniques for identifying her2-low breast cancer tumors | Pending | 10-Jul-2023 | ||
| US-20240347211-A1 | Pan-cancer tumor microenvironment classification based on immune escape mechanisms and immune infiltration | Pending | 13-Apr-2023 | ||
| US-20240295486-A1 | Systems and methods for analyzing cytometry data | Pending | 01-Mar-2023 | ||
| US-20240177803-A1 | Comprehensive immunoprofiling of peripheral blood | Pending | 17-Nov-2022 | G16B25/10 |
BostonGene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BostonGene Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Impact Investment Capital | Impact Investing | Minority | ||
| Japan Industrial Partners | PE/Buyout | Minority | ||
| NEC (Japan) | Holding Company | Minority |
BostonGene Investments (1)
BostonGene’s most recent deal was a Joint Venture with BostonGene Japan. The deal was made on 24-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BostonGene Japan | 24-Aug-2023 | Joint Venture | Other Healthcare Technology Systems |
BostonGene FAQs
-
When was BostonGene founded?
BostonGene was founded in 2015.
-
Where is BostonGene headquartered?
BostonGene is headquartered in Waltham, MA.
-
What is the size of BostonGene?
BostonGene has 300 total employees.
-
What industry is BostonGene in?
BostonGene’s primary industry is Decision/Risk Analysis.
-
Is BostonGene a private or public company?
BostonGene is a Private company.
-
What is the current valuation of BostonGene?
The current valuation of BostonGene is .
-
What is BostonGene’s current revenue?
The current revenue for BostonGene is .
-
How much funding has BostonGene raised over time?
BostonGene has raised $320M.
-
Who are BostonGene’s investors?
Impact Investment Capital, Japan Industrial Partners, and NEC (Japan) have invested in BostonGene.
-
Who are BostonGene’s competitors?
Congenica, Proscia, PierianDx, GenoSpace, and Arterys are some of the 29 competitors of BostonGene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
